HCB2 Ligand-interaction landscape: Cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation

Chemistry and Biology

Volumn 17, Issue 10, 2010, Pages 1132-1142

  Mercier, Richard W ^a,b   Pei, Ying ^a   Pandarinathan, Lakshmipathi ^b   Janero, David R ^b   Zhang, Jing ^a   Makriyannis, Alexandros ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL) 4 (3 HYDROXYPROPYL)CYCLOHEXANOL; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; CANNABINOID 2 RECEPTOR; CYCLOHEXANOL DERIVATIVE; CYSTEINE; LIGAND; PYRAZOLE DERIVATIVE; TRITIUM;

AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; CYCLOHEXANOLS; CYSTEINE; HEK293 CELLS; HUMANS; LIGANDS; PROTEIN BINDING; PYRAZOLES; RECEPTOR, CANNABINOID, CB2; TRITIUM;

EID: 78049396160     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2010.08.010     Document Type: Article

References (50)

1. 2 receptors and the endocannabinoid system for treatment of pain Brain. Res. Rev. 60 2009 255 266
2. J.A. Ballesteros, and H. Weinstein Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors P.M. Conn, S.M. Sealfon, Methods in Neuroscience Volume 25 1995 Academic Press San Diego, CA 366 428
3. M. Bayewitch, T. Avidor-Reiss, R. Levy, J. Barg, R. Mechoulam, and Z. Vogel The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling FEBS Lett. 375 1995 143 147
4. A. Ben-Shlomo, C. Zhou, O. Pichurin, V. Chesnokova, N.-A. Liu, M.D. Culler, and S. Melmed Constitutive somatostatin receptor activity determines tonic pituitary cell response Mol. Endocrinol. 23 2009 337 348
5. T. Benned-Jensen, and M.M. Rosenkilde Structural motifs of importance for the constitutive activity of the orphan 7TM receptor EBI2: analysis of receptor activation in the absence of an agonist Mol. Pharmacol. 74 2008 1008 1021
6. S. Björk, M. Vainio, and M. Scheinin Uneven cellular expression of recombinant alpha2A-adrenoceptors in transfected CHO cells results in loss of response in adenylyl cyclase inhibition Biochim. Biophys. Acta 1744 2005 38 46
7. D.B. Bylund, J.D. Deupree, and M.L. Toews Radioligand-binding methods for membrane preparations and intact cells Methods Mol. Biol. 259 2004 1 28
8. J.Z. Chen, X.W. Han, Q. Liu, A. Makriyannis, J. Wang, and X.Q. Xie 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach J. Med. Chem. 49 2006 625 636
9. M. Congreve, and F. Marshall The impact of GPCR structures on pharmacology and structure-based drug design Br. J. Pharmacol. 159 2010 986 996
10. 2-adrenergic receptor reveals important clues for cannabinoid receptors Cell. Mol. Life Sci. 65 2008 2277 2279
11. G.D. Dalton, C.E. Bass, C.G. Van Horn, and A.C. Howlett Signal transduction via cannabinoid receptors CNS Neurol. Disord. Drug Targets 8 2009 422 431
12. X. Deupi, M. Olivella, C. Govaerts, J.A. Ballesteros, M. Campillo, and L. Pardo Ser and Thr residues modulate the conformation of pro-kinked transmembrane α-helices Biophys. J. 86 2004 105 115
13. V. Di Marzo The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation Pharmacol. Res. 60 2009 77 84
14. J.H. Dunham, and R.A. Hall Enhancement of the surface expression of G protein-coupled receptors Trends Biotechnol. 27 2009 541 545
15. S. Durdagi, M.G. Papadopoulos, P.G. Zoumpoulakis, C. Koukoulitsa, and T. Mavromoustakos A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: homology modeling, docking, de novo drug design and molecular dynamics analysis Mol. Divers. 14 2009 257 276
16. W. Feng, and Z.H. Song Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor Biochem. Pharmacol. 65 2003 1077 1085
17. S.V. Frye The art of the chemical probe Nat. Chem. Biol. 6 2010 159 161
18. P. Gouldson, B. Calandra, P. Legoux, A. Kerneis, M. Rinaldi-Carmona, F. Barth, G. Le Fur, P. Ferrara, and D. Shire Mutational analysis and molecular modelling of the antagonist SR144528 binding site on the human cannabinoid CB(2) receptor Eur. J. Pharmacol. 401 2000 17 25
19. M.A. Hanson, and R.C. Stevens Discovery of new GPCR biology: one receptor structure at a time Structure 17 2009 8 14
20. D.R. Janero, and A. Makriyannis Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Expert Opin. Emerg. Drugs 14 2009 43 65
21. D.R. Janero, S.K. Vadivel, and A. Makriyannis Pharmacotherapeutic modulation of the endocannabinoid signaling system in psychiatric disorders: drug-discovery strategies Int. Rev. Psychiatry 21 2009 122 133
22. 2A-adrenoreceptors Mol. Pharmacol. 53 1998 963 968
23. T. Kokkola, J.R. Savinainen, K.S. Mönkkönen, M.D. Retamal, and J.T. Laitinen S-nitrosothiols modulate G protein-coupled receptor signaling in a reversible and highly receptor-specific manner BMC Cell Biol. 6 2005 21
24. 1 receptor J. Pharmacol. Exp. Ther. 281 1997 761 768
25. 1 dopamine receptor Mol. Pharmacol. 52 1997 1137 1149
26. R. Lan, Q. Liu, P. Fan, S. Lin, S.R. Fernando, D. McCallion, R. Pertwee, and A. Makriyannis Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists J. Med. Chem. 42 1999 769 776
27. Q.R. Liu, C.H. Pan, A. Hishimoto, C.Y. Li, Z.X. Xi, A. Llorente-Berzal, M.P. Viveros, H. Ishiguro, T. Arinami, E.S. Onaivi, and G.R. Uhl Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands Genes Brain Behav. 8 2009 519 530
28. 2 receptor inverse agonists Br. J. Pharmacol. 153 2008 226 239
29. 2 receptor-mediated migration of immune cells: it can go either way Br. J. Pharmacol. 153 2008 299 308
30. S. Mukherjee, M. Adams, K. Whiteaker, A. Daza, K. Kage, S. Cassar, M. Meyer, and B.B. Yao Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors Eur. J. Pharmacol. 505 2004 1 9
31. 1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a Mol. Pharmacol. 72 2007 1557 1566
32. S.L. Palmer, G.A. Thakur, and A. Makriyannis Cannabinergic ligands Chem. Phys. Lipids 121 2002 3 19
33. Y. Pei, R.W. Mercier, J.K. Anday, G.A. Thakur, A.M. Zvonok, D. Hurst, P.H. Reggio, D.R. Janero, and A. Makriyannis Ligand-binding architecture of human CB2 cannabinoid receptor: Evidence for receptor subtype-specific binding motif and modeling GPCR activation Chem. Biol. 15 2008 1207 1219
34. R.P. Picone, A.D. Khanolkar, W. Xu, L.A. Ayotte, G.A. Thakur, D.P. Hurst, M.E. Abood, P.H. Reggio, D.J. Fournier, and A. Makriyannis (-)-7′- Isothiocyanato-11-hydroxy-1′,1′-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor Mol. Pharmacol. 68 2005 1623 1635
35. M. Portier, M. Rinaldi-Carmona, F. Pecceu, T. Combres, C. Poinot-Chazel, B. Calandra, F. Barth, G. Le Fur, and P. Casellas SR144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist J. Pharmacol. Exp. Ther. 288 1999 582 589
36. A. Poso, and J.W. Huffman Targeting the cannabinoid CB2 receptor: modeling and structural determinants of CB2 selective ligands Br. J. Pharmacol. 153 2008 335 346
37. 2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats J. Pharmacol. Exp. Ther. 327 2008 584 591
38. M. Rinaldi-Carmona, F. Barth, J. Millan, J.-M. Derocq, P. Casellas, C. Cogny, D. Oustric, M. Sarran, M. Bouaboula, and B. Calandra SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor J. Pharmacol. Exp. Ther. 284 1998 644 650
39. 1 receptor converts AM2233 from receptor agonist to inverse agonist Eur. J. Pharmacol. 531 2006 41 46
40. D. Shire, B. Calandra, M. Bouaboula, F. Barth, M. Rinaldi-Carmona, P. Casellas, and P. Ferrara Cannabinoid receptor interaction with the antagonists SR 141716A and SR 144528 Life Sci. 65 1999 627 635
41. 1 adenosine receptors stably expressed in Chinese hamster ovary cells Mol. Pharmacol. 53 1998 886 893
42. Q. Tao, S.D. McAllister, J. Andreassi, K.W. Nowell, G.A. Cabral, D.P. Hurst, K. Bachtel, M.C. Ekman, P.H. Reggio, and M.E. Abood Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity Mol. Pharmacol. 55 1999 605 613
43. E.K. Tiburu, S.V. Gulla, M. Tiburu, D.R. Janero, D.E. Budil, and A. Makriyannis Dynamic conformational responses of a human cannabinoid receptor-1 helix domain to its membrane environment Biochemistry 48 2009 4895 4904
44. E.K. Tiburu, S. Tyukhtenko, L. Deshmukh, O. Vinogradova, D.R. Janero, and A. Makriyannis Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments Biochem. Biophys. Res. Commun. 384 2009 243 248
45. S. Topiol, and M. Sabio X-ray structure breakthroughs in the GPCR transmembrane region Biochem. Pharmacol. 78 2009 11 20
46. 3 antagonists J. Pharmacol. Exp. Ther. 299 2001 908 914
47. W. Xu, S.A. Filppula, R. Mercier, S. Yaddanapudi, S. Pavlopoulos, J. Cai, W.M. Pierce, and A. Makriyannis Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system J. Pept. Res. 66 2005 138 150
48. R. Zhang, D.P. Hurst, J. Barnett-Norris, P.H. Reggio, and Z.H. Song Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template Mol. Pharmacol. 68 2005 69 83
49. N. Zvonok, L. Pandarinathan, J. Williams, M. Johnston, I. Karageorgos, D.R. Janero, S.C. Krishnan, and A. Makriyannis Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis Chem. Biol. 15 2008 854 862
50. N. Zvonok, W. Xu, J. Williams, D.R. Janero, S.C. Krishnan, and A. Makriyannis Mass spectrometry-based GPCR proteomics: comprehensive characterization of the human cannabinoid 1 receptor J. Proteome Res. 9 2010 1746 1753